Literature DB >> 23601832

Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: rationale for monitoring premalignant oral lesions in a multidisciplinary clinic.

M W Ho1, E A Field, J K Field, J M Risk, B P Rajlawat, S N Rogers, J C Steele, A Triantafyllou, J A Woolgar, D Lowe, R J Shaw.   

Abstract

Surveillance of oral epithelial dysplasia results in a number of newly diagnosed cases of oral squamous cell carcinoma (SCC). The clinical stage of oral SCC at diagnosis influences the magnitude of treatment required and the prognosis. We aimed to document the stage, treatment, and outcome of oral SCC that arose in patients who were being monitored for oral epithelial dysplasia in a dedicated multidisciplinary clinic. Those with histologically diagnosed lesions were enrolled on an ethically approved protocol and molecular biomarker study. Details of clinical and pathological TNM, operation, radiotherapy, recurrence, second primary tumour, and prognosis, were recorded in patients whose lesions underwent malignant transformation. Of the 91 patients reviewed (median follow-up 48 months, IQR 18-96), 23 (25%) had malignant transformation. All were presented to the multidisciplinary team with stage 1 disease (cT1N0M0). Of these, 21 were initially treated by wide local excision, 2 required resection of tumour and reconstruction, and 2 required adjuvant radiotherapy. At follow-up 3 had local recurrence, one had regional recurrence, one had metachronous lung cancer, and 5 had second primary oral SCC. There were further diagnoses of oral dysplasia in 5 during follow-up, and it is estimated that 76% of patients will have one or other event in 5 years. Disease-specific survival was 100% and overall survival was 96% (22/23). Median follow-up after diagnosis of oral SCC was 24 months (IQR 11-58). Specialist monitoring of oral epithelial dysplasia by a multidisciplinary team allows oral SCC to be detected at an early stage, and enables largely curative treatment with simple and usually minor surgical intervention. The high incidence of second primary oral SCC in high-risk patients with oral epithelial dysplasia further supports intensive targeted surveillance in this group.
Copyright © 2013 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Laser oral cancer; Malignant transformation; Oral cancer; Oral dysplasia; Potentially malignant oral lesion; Recurrence oral cancer; Recurrence oral dysplasia; Survival oral cancer; Treatment oral cancer

Mesh:

Year:  2013        PMID: 23601832     DOI: 10.1016/j.bjoms.2013.03.014

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  13 in total

1.  Double reporting and second opinion in head and neck pathology.

Authors:  Julia A Woolgar; Asterios Triantafyllou; Lester D R Thompson; Jennifer L Hunt; James S Lewis; Michelle D Williams; Antonio Cardesa; Alessandra Rinaldo; Leon Barnes; Pieter J Slootweg; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-17       Impact factor: 2.503

Review 2.  Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time.

Authors:  Joel B Epstein; Pelin Güneri; Andrei Barasch
Journal:  Support Care Cancer       Date:  2014-03-28       Impact factor: 3.603

3.  Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial.

Authors:  Susan R Mallery; Meng Tong; Brian S Shumway; Alice E Curran; Peter E Larsen; Gregory M Ness; Kelly S Kennedy; George H Blakey; George M Kushner; Aaron M Vickers; Brian Han; Ping Pei; Gary D Stoner
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

4.  Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes. Fenretinide's Chemopreventive Mechanisms Include ECM Interactions.

Authors:  Byungdo B Han; Suyang Li; Meng Tong; Andrew S Holpuch; Richard Spinney; Daren Wang; Michael B Border; Zhongfa Liu; Sachin Sarode; Ping Pei; Steven P Schwendeman; Susan R Mallery
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-24

5.  Mutations in p53 Gene Exons in a Sample from the South of Spain in Oral Cancer.

Authors:  Guiomar Martín-Lozano; Raquel Gómez-Díaz; Fernando Iglesías-Martín; Daniel Torres-Lagares; Aida Gutiérrez-Corrales; José-Luis Gutiérrez-Pérez
Journal:  J Clin Exp Dent       Date:  2021-10-01

6.  Targeting of chemoprevention to high-risk potentially malignant oral lesions: challenges and opportunities.

Authors:  Victor D Martinez; Calum E MacAulay; Martial Guillaud; Wan L Lam; Lewei Zhang; Kitty K Corbett; Miriam P Rosin
Journal:  Oral Oncol       Date:  2014-09-16       Impact factor: 5.337

7.  Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines.

Authors:  R Shaw; N Beasley
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

8.  The genomic road to invasion-examining the similarities and differences in the genomes of associated oral pre-cancer and cancer samples.

Authors:  Henry M Wood; Catherine Daly; Rebecca Chalkley; Burcu Senguven; Lisa Ross; Philip Egan; Preetha Chengot; Jennifer Graham; Neeraj Sethi; Thian K Ong; Kenneth MacLennan; Pamela Rabbitts; Caroline Conway
Journal:  Genome Med       Date:  2017-06-07       Impact factor: 11.117

9.  Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders.

Authors:  Yen-Yun Wang; Yen-Hsuan Tail; Wen-Chen Wang; Ching-Yi Chen; Yu-Hsun Kao; Yuk-Kwan Chen; Chung-Ho Chen
Journal:  BMC Oral Health       Date:  2014-08-05       Impact factor: 2.757

10.  Improvement in the risk assessment of oral leukoplakia through morphology-related copy number analysis.

Authors:  Xiaotian Li; Lu Liu; Jianyun Zhang; Ming Ma; Lisha Sun; Xuefen Li; Heyu Zhang; Jianbin Wang; Yanyi Huang; Tiejun Li
Journal:  Sci China Life Sci       Date:  2021-08-02       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.